Ioflupane (123i) Rotop

Ioflupane I-123, the active ingredient in Ioflupane (123i) Rotop, is a radiopharmaceutical presented as a solution for injection for intravenous use. It is used for diagnostic imaging of dopaminergic neuron integrity in patients with suspected Parkinsonian syndromes and other movement disorders.

GNH USA supplies Ioflupane (123i) Rotop as a licensed, GDP-compliant international pharmaceutical supplier serving hospitals, clinics and diagnostic centres worldwide.

Ioflupane I-123 is used in nuclear medicine to assess the dopaminergic system in movement disorder imaging. - Parkinsonian syndrome: assists in differential diagnosis by visualizing dopamine transporter loss. - Multiple system atrophy: helps differentiate from Parkinson's disease through transporter imaging. - Essential tremor: provides information on dopaminergic involvement to guide clinical decisions.

Adverse reactions may occur following administration of Ioflupane I-123.

Common Side Effects: - Injection site pain: mild discomfort at the injection site. - Nausea: transient feeling of queasiness. - Headache: mild to moderate headache. - Transient flushing: brief skin redness.

Serious or Rare Side Effects: - Allergic reaction (anaphylaxis): severe hypersensitivity requiring immediate medical attention. - Severe hypotension: marked drop in blood pressure. - Radiation‑induced thyroid dysfunction: potential impact on thyroid function due to radioactive exposure.

Prior to use, consider the following safety measures. - Pregnancy: safety not established; avoid unless essential. - Breastfeeding: unknown safety; weigh potential risks. - Renal impairment: assess because clearance may be altered. - Thyroid disorders: evaluate risk of radiation exposure to the thyroid gland. - Concomitant iodine: excess iodine may interfere with tracer uptake. - Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

Ioflupane I-123 may interact with other substances that affect iodine handling or dopamine imaging.

Major Interactions (Avoid): - Iodine‑containing contrast agents: can compete with Ioflupane binding. - Thyroid hormone therapy: may alter radiotracer distribution.

Moderate Interactions (Monitor Closely): - Anticholinergic drugs: may affect dopaminergic imaging interpretation. - MAO inhibitors: potential impact on dopamine transporter activity. - Caffeine: can modestly influence SPECT signal.